From the Guidelines
Maintenance treatment for atrial fibrillation typically involves a combination of rate control, rhythm control, and stroke prevention strategies, with a focus on reducing symptoms, preventing stroke, and improving quality of life, as recommended by the 2024 ESC guidelines 1.
Key Components of Maintenance Treatment
- Rate control: beta-blockers (metoprolol 25-200 mg daily, carvedilol 3.125-25 mg twice daily, or bisoprolol 2.5-10 mg daily) or calcium channel blockers (diltiazem 120-360 mg daily or verapamil 120-360 mg daily) are first-line options to maintain heart rate below 110 beats per minute, as supported by the 2024 ESC guidelines 1.
- Rhythm control: antiarrhythmic medications such as flecainide (50-200 mg twice daily), propafenone (150-300 mg three times daily), amiodarone (200 mg daily after loading), or sotalol (80-160 mg twice daily) may be prescribed for patients with symptomatic AFib, with consideration of the patient's symptoms, comorbidities, and stroke risk as assessed by the CHA₂DS₂-VASc score.
- Stroke prevention: anticoagulation with direct oral anticoagulants (DOACs) like apixaban (5 mg twice daily), rivaroxaban (20 mg daily), dabigatran (150 mg twice daily), or edoxaban (60 mg daily), or warfarin (dose adjusted to maintain INR 2-3) is crucial, with the choice of anticoagulant depending on the patient's individual risk of thromboembolism and bleeding, as recommended by the 2024 ESC guidelines 1.
Additional Considerations
- Lifestyle modifications: weight loss, exercise, blood pressure control, and reducing alcohol consumption are important components of long-term AFib management, as they can help reduce symptoms and improve quality of life.
- Regular monitoring: kidney function, liver function, and medication effectiveness should be regularly monitored to adjust therapy as needed, with consideration of the potential risks and benefits of each treatment option, as discussed in the 2001 ACC/AHA/ESC guidelines 2.
Prioritizing Morbidity, Mortality, and Quality of Life
The primary goal of maintenance treatment for atrial fibrillation is to reduce morbidity, mortality, and improve quality of life, with a focus on individualized treatment strategies that take into account the patient's unique needs and risk factors, as recommended by the 2024 ESC guidelines 1.
From the FDA Drug Label
Peak digoxin body stores larger than the 8 to 12 mcg/kg required for most patients with heart failure and normal sinus rhythm have been used for control of ventricular rate in patients with atrial fibrillation Doses of digoxin used for the treatment of chronic atrial fibrillation should be titrated to the minimum dose that achieves the desired ventricular rate control without causing undesirable side effects. Nonvalvular Atrial Fibrillation: 15 or 20 mg, once daily with food
The typical regimens for maintenance treatment of atrial fibrillation (afib) are:
- Digoxin: the dose should be titrated to the minimum dose that achieves the desired ventricular rate control without causing undesirable side effects, with peak body stores larger than 8 to 12 mcg/kg often used for control of ventricular rate 3
- Rivaroxaban: 15 or 20 mg, once daily with food 4
From the Research
Typical Regimens for Atrial Fibrillation Maintenance
The treatment aims for atrial fibrillation (afib) are to reduce patients' symptoms and prevent embolism and deterioration of any underlying heart disease 5.
Rate Control vs Rhythm Control
- Rate control is often the first-line option, using digoxin, beta-blockers (other than sotalol), or calcium channel blockers (diltiazem or verapamil) 5, 6, 7.
- Rhythm control may be considered in symptomatic, recent, or paroxysmal atrial fibrillation in patients under 65 who have no signs or symptoms of coronary heart disease, using amiodarone and/or electrical cardioversion 5.
- Antiarrhythmic drug therapy may be used to produce cardioversion, facilitate electrical conversion, prevent early reversion after cardioversion, maintain sinus rhythm, or facilitate conversion of fibrillation to flutter 7.
Anticoagulation Therapy
- Anticoagulation or antiplatelet therapy is essential in preventing thromboembolic complications, with warfarin preferred in older or high-risk patients 6, 7, 8.
- Novel therapeutic options, such as surgical or percutaneous exclusion or occlusion of the left atrial appendage, have evolved to reduce thromboembolic complications 8.
Treatment Considerations
- Treatment must be combined with anticoagulant or antiplatelet therapy and treatment of any underlying heart disease 5, 6, 7.
- The choice of antiarrhythmic drug is guided by efficacy, convenience, cost, and safety considerations, with agents having serious organ toxicity potential and proarrhythmic risk avoided as first-line choices 7.